Arcadia Biosciences
RKDA
22 hedge funds and large institutions have $1.71M invested in Arcadia Biosciences in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
47% more call options, than puts
Call options by funds: $53K | Put options by funds: $36K
0.02% less ownership
Funds ownership: 0.22% → 0.19% (-0.02%)
12% less funds holding
Funds holding: 25 → 22 (-3)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
36% less capital invested
Capital invested by funds: $2.69M → $1.71M (-$978K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$59.5K |
| 2 |
Millennium Management
New York
|
+$29K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.5K |
| 4 |
SG
StoneX Group
New York
|
+$15.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$122K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$80.8K |
| 3 |
Jane Street
New York
|
-$51K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$49K |
| 5 |
BlackRock
New York
|
-$31.4K |
RKDA Hedge Fund Activity: Q2 2022 in Review
22 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q2 2022, worth a combined $1.71M — down 36% from $2.69M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RKDA and 3 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $59.5K. The largest seller was Susquehanna International Group, cutting an estimated $122K.
- 22 institutional investors held Arcadia Biosciences (RKDA) as of Q2 2022, down from 25 in Q1 2022.
- Funds reported $1.71M of Arcadia Biosciences stock for Q2 2022, down 36% quarter-over-quarter.
- 3 funds opened new Arcadia Biosciences positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Arcadia Biosciences buyer in Q2 2022 was Renaissance Technologies, an estimated $59.5K added.
- The largest Arcadia Biosciences seller in Q2 2022 was Susquehanna International Group, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2022.